Combo Tx for Melanoma Ups CV Risk

Source: Medpage Today, September 2019

Dual BRAF and MEK inhibition therapy for melanoma may carry certain cardiovascular harms, according to a meta-analysis.

Across five randomized trials with a total of 2,317 patients, the addition of MEK inhibition to a BRAF inhibitor, in comparison with BRAF inhibitor monotherapy, was associated with certain cardiovascular adverse events:

• Pulmonary embolism: RR 4.36 (95% CI 1.23-15.44)